Research Article: Pharmacological Profile and Tissue Selectivity of Andarine (S-4)

Abstract

Andarine (also known as S-4 or GTx-007) is an early-generation, nonsteroidal selective androgen receptor modulator (SARM) belonging to the aryl propionamide class. Developed initially for the treatment of conditions such as muscle wasting and osteoporosis, Andarine demonstrates high affinity for the androgen receptor (AR) and exhibits significant tissue selectivity. In preclinical models, it functions as a potent agonist in skeletal muscle and bone while acting as a partial agonist/antagonist in androgenic tissues like the prostate. Despite its robust anabolic efficacy in animal studies, its clinical development was hindered by unique ocular side effects—specifically a yellow-tinted visual disturbance (xanthopsia). This article reviews the mechanism of action, preclinical evidence, pharmacokinetics, and safety profile of Andarine based on available peer-reviewed literature.

Mechanism of Action

Andarine functions as a high-affinity ligand for the androgen receptor ($K_i \approx 4\text{ nM}$). Unlike traditional anabolic-androgenic steroids (AAS), Andarine is nonsteroidal and does not undergo conversion to dihydrotestosterone (DHT) via 5$\alpha$-reductase, nor does it aromatize into estrogen.

The compound exhibits a high degree of tissue selectivity. In skeletal muscle, it acts as a full agonist, stimulating protein synthesis and increasing lean mass. In the prostate and seminal vesicles, Andarine demonstrates reduced potency and intrinsic activity compared to testosterone, effectively acting as a partial agonist or competitive antagonist in the presence of endogenous androgens. This selectivity is hypothesized to result from the differential recruitment of transcriptional co-activators and co-repressors upon binding to the AR in various tissues.

A unique pharmacological feature of Andarine is its interaction with the visual system. Research suggests that the S-4 molecule binds to the rhodopsin protein within the retina. This interaction alters the recovery rate of the visual cycle, leading to the characteristic "yellow vision" and impaired night vision reported in anecdotal human use and observed during early clinical assessments.

Clinical Evidence

Most peer-reviewed data regarding Andarine is derived from in vivo animal models. While GTx, Inc. conducted early Phase I human trials, the comprehensive results were largely kept proprietary, and the compound was eventually deprioritized in favor of Enobosarm (Ostarine).

In Vivo Animal Studies

Animal research has consistently demonstrated Andarine’s ability to prevent bone loss and muscle atrophy. In orchidectomized (ORX) rat models—the gold standard for testing SARMs—Andarine administration successfully maintained levator ani muscle weight (a marker of anabolic activity) at levels comparable to testosterone propionate, while maintaining prostate weights at only 15–20% of intact controls.

Studies in osteopenic female rats showed that Andarine could increase bone mineral density (BMD) and cortical strength. Unlike testosterone, which can cause virilization in females, Andarine showed a wider therapeutic window between beneficial bone effects and undesirable androgenic effects on reproductive tissues.

Pharmacokinetics

In animal models (primarily rats and canines), Andarine exhibits high oral bioavailability. It has a relatively short terminal half-life compared to second-generation SARMs, estimated at approximately 3 to 4 hours in humans, which often necessitates multiple daily doses in experimental settings to maintain stable plasma concentrations. It is primarily metabolized through hepatic pathways.

Safety Profile & Adverse Effects

The safety profile of Andarine is characterized by two distinct categories: hormonal suppression and ocular disturbances.

1. •HPTA Suppression: Like all AR ligands, Andarine causes dose-dependent suppression of the Hypothalamic-Pituitary-Testicular Axis (HPTA). This results in decreased endogenous testosterone, Luteinizing Hormone (LH), and Follicle-Stimulating Hormone (FSH).
2. •Ocular Side Effects (Xanthopsia): The most notable adverse effect is a yellow-tinted vision and difficulty adjusting to low-light environments (nyctalopia). This occurs because Andarine binds to the light-sensitive proteins in the eye. While these effects were reported as reversible upon cessation of the compound, they significantly hampered the drug's clinical viability.
3. •Lipid Profile: Preclinical data suggests a potential reduction in HDL cholesterol, a common side effect associated with oral androgenic compounds.
4. •Hepatotoxicity: While significant elevations in liver enzymes were not widely reported in early trials, the aryl propionamide structure requires cautious monitoring for potential strain on hepatic function during prolonged use.

Research Limitations & Evidence Gaps

The primary limitation of Andarine research is the lack of published Phase II and Phase III human clinical trials. Consequently, the long-term safety, cardiovascular impact, and definitive metabolic profile in humans remain unknown. Furthermore, because Andarine is not FDA-approved for human use, much of the contemporary "data" stems from unregulated "grey market" usage, which lacks the rigor of controlled clinical environments. The precise molecular mechanism by which Andarine interacts with retinal rhodopsin also requires further biochemical elucidation.

References

1. •Gao W. et al., "Effects of a novel selective androgen receptor modulator (SARM) on skeletal muscle and prostate in vivo", Endocrinology, 2004. DOI: 10.1210/en.2004-0057 (In Vivo - Animal)
2. •Yin D. et al., "Pharmacodynamics of Selective Androgen Receptor Modulators", Journal of Pharmacology and Experimental Therapeutics, 2003. DOI: 10.1124/jpet.102.044123 (In Vivo - Animal)
3. •Kim J. et al., "The Tissue Selectivity of Novel Nonsteroidal Selective Androgen Receptor Modulators Is Mediated by Differential Activities of Coregulators", Journal of Biological Chemistry, 2003. DOI: 10.1074/jbc.M303938200 (In Vitro)
4. •Kearbey J.D. et al., "Selective Androgen Receptor Modulator (SARM) Treatment Maintains Bone Mass and Muscle Strength in Osteopenic Rats", Pharmaceutical Research, 2007. DOI: 10.1007/s11095-006-9155-8 (In Vivo - Animal)
5. •Zhang X. et al., "Design, Synthesis, and In Vivo Biological Evaluation of Novel Nonsteroidal Androgen Receptor Antagonists", Journal of Medicinal Chemistry, 2007. DOI: 10.1021/jm0613840 (In Vivo / In Vitro)
6. •Mohler M.L. et al., "Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor", Journal of Medicinal Chemistry, 2009. DOI: 10.1021/jm9002806 (Review)